Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings vs Current Targeting Procedure

Parkinson Disease Clinical Trial

— PARKEO2  

Official title:

Deep Brain Stimulation for Parkinson's Disease: Probabilistic STN Targeting Under General Anaesthesia Without Micro-electrode Recordings (MER) vs Current Targeting Procedure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04884412
• Other study ID #: CHUBX 2019/54
• Status: Recruiting
• Phase: N/A
• Start date: November 10, 2021
• Est. completion date: November 2026

Study information

• Verified date: November 2023
• Source: University Hospital, Bordeaux
• Contact: Emmanuel CUNY, Pr
• Phone: 05 56 79 55 77
• Email: emmanuel.cuny[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Deep brain stimulation (DBS) of the sub-thalamic nucleus (STN) has evolved over the past decades as a mainstream therapy for advanced Parkinson's disease (PD). The classical procedure consists in STN indirect targeting based on stereotactic atlases or statistical coordinates in AC-PC (Anterior Commissure - Posterior Commissure) referential along with target control and correction by micro-electrode recordings (MER) and awake clinical testing. To avoid potential complications and patient discomfort related to current procedure, asleep surgery without this control process has become more and more performed, essentially thanks to the progress of neuroimaging allowing to STN visualization. However, it has been reported a relative inaccuracy between the "radiological" STN delimitated on several types of MRI sequences (T2, T2*, SWI) and the per-operative electrophysiological findings. As a result, there are currently many types of STN-DBS procedures, and the lack of standardization between techniques complicates the interpretation of postoperative results on anatomical, electrophysiological and clinical points of view. Furthermore, to date, it has not been proven that asleep surgery without MER and clinical controls is as effective as the standard procedure in a prospective controlled randomized clinical trial.

Investigators hypothesize that the clinical-based 18 landmarks STN target will be precise enough to allow to perform surgery under general anesthesia without MER correction, and accurate enough to achieve non inferior clinical results compared to what is usually done in each centre.

The main objective is to compare at one year, the % of motor improvement after PARKEO 2-targeting asleep DBS without intraoperative MER versus the targeting procedure using intraoperative MER by the UPRDRS 3 (Unified Parkinson's disease rating scale 3).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 128
• Est. completion date: November 2026
• Est. primary completion date: November 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of idiopathic Parkinson's disease at the stage of motor fluctuations despite optimal medical treatment

• L-DOPA sensitivity defined by motor improvement above 50% on the UPDRS-3 scale after a dose of 150% of the usual early morning treatment

• Indication for STN-DBS approved by the local multidisciplinary movement disorders committee.

• Patients between 18 and 70 years of age

• Patients covered by a health insurance scheme

• Signed informed consent.

Exclusion Criteria:

• Significant cognitive decline defined as a score < 22 on the MoCA scale

• Mood disorders defined by a score > 20 on the Beck Depression Inventory

• Significant cortical atrophy or leukoencephalopathy visualised by brain MRI

• Contraindication to anaesthesia and MRI

• Lack of contraceptive treatment for women with ability to procreate

• Pregnant or breast-feeding woman

• Unstoppable anticoagulant or antiaggregant treatment

• Persons under legal protection (Persons deprived of liberty or incapable of giving consent or under curatorship or tutorship…)

• Patient with severe psychiatric disorders (on Diagnostic and Statistical Manual of Mental Disorders IV)

• Inability to follow the patient until the end of study

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Procedure:
• Surgery under general anesthesia with experimental targeting
Surgery will be performed under general anesthesia. The electrodes will be inserted directly on the targets without MER, with PARKEO_2 targets provided by the Bordeaux University Hospital, based on the machine-learning model developed in Bordeaux.
• Usual Surgery
In the control group, surgery will be performed as usual in each centre under local or general anaesthesia. This group represents the current state of the art of deep brain stimulation in these centres.

Locations

Country	Name	City	State
France	CHU Amiens	Amiens
France	CHU de Bordeaux	Bordeaux
France	CHU Grenoble	Grenoble
France	Hospices Civils de Lyon	Lyon
France	CHU Marseille	Marseille
France	CHRU de Nancy	Nancy
France	CHU de Nice	Nice
France	CHU de Rouen	Rouen
France	CHU de Strasbourg	Strasbourg
France	CHU de Toulouse	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stimulation efficacy	The primary endpoint is the efficacy of the stimulation on motor symptoms assessed by the change in UPDRS-3 scores between OFF and ON stimulation evaluations at one year after surgery without any medical treatment (OFF medication).; Unified Parkinson's Disease Rating Scale 3 (UPDRS 3) questionnaire: 0 to 132 points, with the highest score indicating worsening	12 months after surgery (M12)
Secondary	Quality of life assessment	Quality of life on the Parkinson Disease Questionnaire 39 (PDQ39) scale assessed by the change in PDQ39 scores.; PDQ 39 questionnaire : 0 to 156 points, with the highest score indicating worsening condition	inclusion (Month-1) and 12 months after surgery (M12)
Secondary	Stereotactic accuracy	Stereotactic accuracy as measured by the Euclidian distance between active contact location and intra-operative defined target in each group	Surgery intervention (Month 0)
Secondary	Operative characteristics (1)	Operative characteristic : procedure length	Surgery intervention (Month 0)
Secondary	Operative characteristics (2)	Operative characteristic : radiation dose	Surgery intervention (Month 0)
Secondary	Operative characteristics (3)	Operative characteristic : pneumocephalus	Surgery intervention (Month 0)
Secondary	Operative characteristics (4)	Operative characteristic : and length of hospital stay (in days).	Surgery intervention (Month 0)
Secondary	Distance between active contact location and preoperative target	Distance between active contact location and preoperative defined target in each group	Surgery intervention (Month 0)
Secondary	Improvement of UPDRS3	The percentage of improvement of UPDRS3 calculated between the preoperative OFF and the post-operative ON stimulation scores at one year and compared between the two groups.; Unified Parkinson's Disease Rating Scale 3 (UPDRS 3) questionnaire: 0 to 132 points, with the highest score indicating worsening	12 months after surgery (M12)
Secondary	Efficacy of the targeting procedure on motor symptoms (1)	The efficacy of the targeting procedure on motor symptoms assessed by the change in UPDRS-3 scores between OFF and ON stimulation evaluations at one year after surgery without any medical treatment (OFF medication). The change will be calculated as a difference between the OFF and ON stimulation scores at one year.; Unified Parkinson's Disease Rating Scale 3 (UPDRS 3) questionnaire: 0 to 132 points, with the highest score indicating worsening	12 months after surgery (M12)
Secondary	Efficacy of the targeting procedure on motor symptoms (2)	The efficacy of the targeting procedure on motor symptoms compared to the efficacy of L-DOPA by the change in UPDRS-3 scores between OFF and ON stimulation evaluations at one year after surgery without any medical treatment (OFF medication). The change will be calculated as a ratio between the effect of stimulation alone versus medication alone at one year.; Unified Parkinson's Disease Rating Scale 3 (UPDRS 3) questionnaire: 0 to 132 points, with the highest score indicating worsening	12 months after surgery (M12)
Secondary	reduction in the levodopa equivalent daily doses (LEDD)	The reduction in the levodopa equivalent daily doses (LEDD) from the baseline and one year (a 100-mg daily dose of standard levodopa is equivalent to the following doses of other medications: 133 mg of controlled-release levodopa; 75 mg of levodopa plus entacapone; 1 mg of pergolide, pramipexole lisuride, or cabergoline; 5 mg of ropinirole; 10 mg of bromocriptine or apomorphine; and 20 mg of dihydroergocryptine) will be evaluated	12 months after surgery (M12)
Secondary	Post-operative cognitive	Post-operative cognitive will be assess by the difference from the baseline and one year using MDRS.; Mattis Dementia Rating Scale: 0 to 144 points, with the most important score indicating improvement in condition	12 months after surgery (M12)
Secondary	Post-operative mood	Post-operative mood will be assess by the difference from the baseline and one year using BDI scale.; Beck Depression Inventory (BDI): 0 to 63 points, with the most important score indicating worsening condition	12 months after surgery (M12)
Secondary	Intra and post-operative surgical complications	Intra and post-operative surgical complications (haemorrhage, infection, neuromodulation-related side effects) will be prospectively collected and assessed	Surgery intervention (Month 0)
Secondary	Total cost of each procedure (PARKEO-2 targeting compared to targeting procedure using intraoperative MER)	A cost analysis will be performed to assess all hospital resources	Surgery intervention (Month 0)
Secondary	Cost-effectiveness ratio, expressed in terms of cost per Qaly gained at 1 year	This ratio will provide useful information about the costs (avoided or additional) required to gain a Qaly, one year after surgery, from the French healthcare system point of view	12 months after surgery (M12)